AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24159791 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexicor used in combined therapy with statins for atherogenic dyslipidemia
Number of subjects: 0
Study 20564380 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ursodeoxycholic acid (UDCA) treatment (28-30 mg/kg/day)
Number of subjects: 56
Study 20564380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 18818707 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard risk patients who relapsed
Number of subjects: 1961
Study 18818707 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients experiencing early relapse (less than 18 months from initial diagnosis)
Number of subjects: 1961
Study 18818707 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (10+ years), presence of central nervous system disease at diagnosis, male gender, and T-cell disease
Number of subjects: 1961
Study 18818707 — intervention group
Group type: COMPARATOR
Intervention: Relapsed patients in earlier vs later era trials
Number of subjects: 1961
Study 16835378 — intervention group
Group type: EXPERIMENTAL
Intervention: Palifermin (40 mug/kg per day for cohort 1, 60 mug/kg per day for cohorts 2 and 3)
Number of subjects: 100
Study 16835378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 12509613 — intervention group
Group type: EXPERIMENTAL
Intervention: Clenoliximab (0.05, 0.2, 1, 5, 10 or 15 mg/kg; 150 or 350 mg weekly x 4; or 350 or 700 mg every other week x 2)
Number of subjects: 12
Study 12509613 — intervention group
Group type: EXPERIMENTAL
Intervention: Clenoliximab (higher doses, less frequently)
Number of subjects: 12
Study 11100963 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-repair therapy including naturally occurring compounds (isoflavonoids), aminoglycoside antibiotics, butyrate analogues, phosphodiesterase inhibitors, adenosine nucleotides, designer compounds (benzo[c]quinoliziniums), small peptide replacements
Number of subjects: 0
Study 8763312 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic polypropylene suture
Number of subjects: 44
Study 8763312 — intervention group
Group type: COMPARATOR
Intervention: Nylon control suture
Number of subjects: 44
Study 2072085 — intervention group
Group type: EXPERIMENTAL
Intervention: Person condition (N = 12) - infants presented with tongue protrusions and mouth openings modeled by an adult.
Number of subjects: 27
Study 2072085 — intervention group
Group type: COMPARATOR
Intervention: Object condition (N = 15) - infants presented with gestures simulated by two objects.
Number of subjects: 27
Study 6414955 — intervention group
Group type: EXPERIMENTAL
Intervention: Deroctyl (sustained-release capsules)
Number of subjects: 8
Study 6414955 — intervention group
Group type: COMPARATOR
Intervention: Euglucon (regular tablets)
Number of subjects: 8
Study 31536162 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser + RAP
Number of subjects: 21
Study 31536162 — intervention group
Group type: COMPARATOR
Intervention: Laser-Only
Number of subjects: 21
Study 30348227 — intervention group
Group type: EXPERIMENTAL
Intervention: Getting To Outcomes (GTO) implementation support intervention for CHOICE
Number of subjects: 29
Study 30348227 — intervention group
Group type: COMPARATOR
Intervention: CHOICE (control group)
Number of subjects: 29
Study 26961114 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive statin therapy (target LDL-C <70 mg/dL)
Number of subjects: 5144
Study 26961114 — intervention group
Group type: COMPARATOR
Intervention: Standard statin therapy (target LDL-C ≥100 and <120 mg/dL)
Number of subjects: 5144
Study 24760537 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 600 or 900 μg twice daily
Number of subjects: 0
Study 24760537 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide treatment
Number of subjects: 0
Study 21547371 — intervention group
Group type: EXPERIMENTAL
Intervention: Very preterm children
Number of subjects: 132
Study 21547371 — intervention group
Group type: COMPARATOR
Intervention: Term children
Number of subjects: 132
Study 20537049 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive working memory training
Number of subjects: 95
Study 20537049 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adaptive working memory training
Number of subjects: 95
Study 20537049 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 95
Study 17681027 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD)
Number of subjects: 20
Study 17681027 — intervention group
Group type: COMPARATOR
Intervention: Control population
Number of subjects: 20
Study 15649196 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg daily for 8 weeks
Number of subjects: 200
Study 15649196 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 200
Study 15144165 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based medicine (EBM) principles and methods
Number of subjects: 0
Study 15144165 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 11165454 — intervention group
Group type: EXPERIMENTAL
Intervention: Oats (3 gm beta-glucan)
Number of subjects: 50
Study 11165454 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (800 IU)
Number of subjects: 50
Study 11165454 — intervention group
Group type: COMPARATOR
Intervention: Wheat cereal (placebo)
Number of subjects: 50
Study 9314627 — intervention group
Group type: EXPERIMENTAL
Intervention: PATHWAYS weight loss program (14 weeks)
Number of subjects: 39
Study 9314627 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 39
Study 8157043 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal butorphanol (2 mg) without oxymetazoline
Number of subjects: 3
Study 8157043 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal butorphanol (2 mg) with oxymetazoline
Number of subjects: 3
Study 8157043 — intervention group
Group type: COMPARATOR
Intervention: Intravenous butorphanol (2 mg)
Number of subjects: 3
Study 3749006 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice plus nicotine gum
Number of subjects: 1328
Study 3749006 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice
Number of subjects: 1328
Study 3749006 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1328
Study 28968138 — intervention group
Group type: EXPERIMENTAL
Intervention: IIV4 (split-virion quadrivalent influenza vaccine)
Number of subjects: 2225
Study 28968138 — intervention group
Group type: COMPARATOR
Intervention: IIV3 (trivalent inactivated influenza vaccine)
Number of subjects: 2225
Study 26223345 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir
Number of subjects: 180
Study 26223345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 22954645 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose of alcohol
Number of subjects: 0
Study 22954645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20692562 — intervention group
Group type: EXPERIMENTAL
Intervention: Transconjunctival single‐plane sclerocorneal incision
Number of subjects: 122
Study 20692562 — intervention group
Group type: COMPARATOR
Intervention: Clear corneal incision (CCI)
Number of subjects: 122
Study 17940203 — intervention group
Group type: EXPERIMENTAL
Intervention: epoetin alpha, epoetin beta, or darbepoetin alpha (DAR) with or without granulocyte colony‐stimulating factor
Number of subjects: 403
Study 17940203 — intervention group
Group type: EXPERIMENTAL
Intervention: epoetin or DAR treatment
Number of subjects: 403
Study 17940203 — intervention group
Group type: EXPERIMENTAL
Intervention: less than 10% blasts, low and int‐1 International Prognostic Scoring System (IPSS), red blood cell transfusion independence, serum EPO level less than 200 IU/L
Number of subjects: 403
Study 17940203 — intervention group
Group type: EXPERIMENTAL
Intervention: major response (IWG 2000 criteria), IPSS low to INT‐1, blasts less than 5%, absence of multilineage dysplasia
Number of subjects: 403
Study 17940203 — intervention group
Group type: EXPERIMENTAL
Intervention: IWG 2000 minor responders
Number of subjects: 403
Study 15908852 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronically homeless (CH)
Number of subjects: 274
Study 15908852 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitionally homeless (TRANS)
Number of subjects: 274
Study 15908852 — intervention group
Group type: COMPARATOR
Intervention: Housed comparison subjects (HSD)
Number of subjects: 274
Study 15908852 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing status
Number of subjects: 274
Study 12554890 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing retraining
Number of subjects: 33
Study 12554890 — intervention group
Group type: COMPARATOR
Intervention: Education control
Number of subjects: 33
Study 10443731 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy with pelvic lymph node dissection
Number of subjects: 95
Study 10443731 — intervention group
Group type: COMPARATOR
Intervention: External beam radiotherapy with endocrine therapy
Number of subjects: 95
Study 7603934 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastery tape
Number of subjects: 42
Study 7603934 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping tape
Number of subjects: 42
Study 7603934 — intervention group
Group type: COMPARATOR
Intervention: General nurse scenes and narration tape
Number of subjects: 42
Study 2192098 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol (160 mg initially, 320 mg subsequently)
Number of subjects: 62
Study 2192098 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (50 mg daily)
Number of subjects: 62
Study 2192098 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oxprenolol (160 mg and 320 mg) and chlorthalidone (25 mg and 50 mg)
Number of subjects: 62
Study 2192098 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol (monotherapy and combination therapy)
Number of subjects: 62
Study 2192098 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (monotherapy)
Number of subjects: 62
Study 343970 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen
Number of subjects: 12
Study 343970 — intervention group
Group type: COMPARATOR
Intervention: aspirin
Number of subjects: 12
Study 29017289 — intervention group
Group type: EXPERIMENTAL
Intervention: Precaine
Number of subjects: 80
Study 29017289 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA mixture
Number of subjects: 80
Study 29017289 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% Lignocaine
Number of subjects: 80
Study 29017289 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% Lignocaine
Number of subjects: 80
Study 27145248 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminders for medication adherence
Number of subjects: 96
Study 27145248 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SMS reminders)
Number of subjects: 96
Study 24200515 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum (COL) 20g daily for 12 weeks
Number of subjects: 53
Study 24200515 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) isoenergetic/isomacronutrient
Number of subjects: 53
Study 22778317 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line erlotinib followed at progression by cisplatin-gemcitabine
Number of subjects: 760
Study 22778317 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (first-line chemotherapy followed by erlotinib)
Number of subjects: 760
Study 21126943 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 24
Study 21126943 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy women)
Number of subjects: 24
Study 18275764 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive and multifactorial intervention
Number of subjects: 71
Study 18275764 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study 15818105 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine to increase mean arterial pressure to 85 mm Hg
Number of subjects: 28
Study 15818105 — intervention group
Group type: COMPARATOR
Intervention: Mean arterial pressure maintained at 65 mm Hg (Control group)
Number of subjects: 28
Study 15818105 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine to maintain mean arterial pressure at 65 mm Hg (Control group)
Number of subjects: 28
Study 12886798 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based participatory intervention
Number of subjects: 28000
Study 12886798 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28000
Study 10233190 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) and two antibiotics (metronidazole, tetracycline) twice daily for 14 days
Number of subjects: 50
Study 7793406 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright exercise
Number of subjects: 20
Study 7793406 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine exercise
Number of subjects: 20
Study 7793406 — intervention group
Group type: COMPARATOR
Intervention: Rest (supine and upright)
Number of subjects: 20
Study 7793406 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest (hypertensive patients)
Number of subjects: 20
Study 2405730 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction drains
Number of subjects: 370
Study 2405730 — intervention group
Group type: EXPERIMENTAL
Intervention: Penrose drains
Number of subjects: 370
Study 2405730 — intervention group
Group type: COMPARATOR
Intervention: No drains
Number of subjects: 370
Study 7418351 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (Primperan) administration prior to examination
Number of subjects: 0
Study 7418351 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Metoclopramide)
Number of subjects: 0
Study 6149595 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluperlapine (200-600 mg/day)
Number of subjects: 11
Study 29696812 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-high-intensity aerobic and resistance exercise intervention (20 weeks)
Number of subjects: 74
Study 29696812 — intervention group
Group type: COMPARATOR
Intervention: Home-based exercise of light intensity (control group)
Number of subjects: 74
Study 29878947 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (NMB) with rocuronium and reversed with sugammadex
Number of subjects: 34
Study 29878947 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (NMB)
Number of subjects: 34
Study 29878947 — intervention group
Group type: COMPARATOR
Intervention: No neuromuscular blockade (NMB)
Number of subjects: 34
Study 27028731 — intervention group
Group type: EXPERIMENTAL
Intervention: Darker backgrounds (black)
Number of subjects: 100
Study 24824548 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 3234
Study 24824548 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin intervention
Number of subjects: 3234
Study 24824548 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 3234
Study 22301884 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen 200 mg/wk
Number of subjects: 32
Study 22301884 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen 300 mg/wk
Number of subjects: 32
Study 22301884 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen 100 mg/wk
Number of subjects: 32
Study 22301884 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen (100, 200, 300 mg/wk)
Number of subjects: 32
Study 22301884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 19655226 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleet ready‐to‐use enema
Number of subjects: 203
Study 19655226 — intervention group
Group type: COMPARATOR
Intervention: Glycerin suppositories
Number of subjects: 203
Study 16762570 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional radiofrequency (CRF)
Number of subjects: 40
Study 16762570 — intervention group
Group type: COMPARATOR
Intervention: Pulsed radiofrequency (PRF)
Number of subjects: 40
Study 16762570 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional radiofrequency (CRF) after PRF
Number of subjects: 40
Study 15917051 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination in practices in the most deprived tertile
Number of subjects: 5572
Study 15917051 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination in the mid SMR tertile
Number of subjects: 5572
Study 15917051 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination in the highest SMR tertile
Number of subjects: 5572
Study 15917051 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination in individuals with poorer quality housing
Number of subjects: 5572
Study 15917051 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination in married individuals or those with respiratory conditions
Number of subjects: 5572
Study 15917051 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination in individuals who smoked, had cognitive impairment, or depression
Number of subjects: 5572
Study 12394530 — intervention group
Group type: EXPERIMENTAL
Intervention: RUL ECT at eight times seizure threshold (ST)
Number of subjects: 77
Study 12394530 — intervention group
Group type: COMPARATOR
Intervention: BL ECT at 1.5 times seizure threshold (ST)
Number of subjects: 77
Study 12394530 — intervention group
Group type: EXPERIMENTAL
Intervention: RUL ECT at eight times ST
Number of subjects: 77
Study 12394530 — intervention group
Group type: COMPARATOR
Intervention: BL ECT at 1.5 times ST
Number of subjects: 77
Study 12394530 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RUL ECT and BL ECT
Number of subjects: 77
Study 10462868 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency department protocol for the identification and acute management of abused women; staff training in protocol use.
Number of subjects: 10961
Study 7885820 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended haptic perception of gap size
Number of subjects: 0
Study 7885820 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulated rotational inertia of the probe
Number of subjects: 0
Study 2229524 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical terbinafine 1% cream
Number of subjects: 27
Study 2229524 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 27
Study 338872 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular iron treatment
Number of subjects: 24
Study 338872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31854285 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-Up (ABC) intervention
Number of subjects: 23
Study 31854285 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 23
Study 31808278 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg monotherapy
Number of subjects: 106
Study 31808278 — intervention group
Group type: COMPARATOR
Intervention: PRP (Panretinal photocoagulation)
Number of subjects: 106
Study 31808278 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ranibizumab 0.5 mg/PRP
Number of subjects: 106
Study 29110753 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright position during second-stage labour
Number of subjects: 3236
Study 29110753 — intervention group
Group type: COMPARATOR
Intervention: Lying-down position during second-stage labour
Number of subjects: 3236
Study 29110753 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright position
Number of subjects: 3236
Study 29110753 — intervention group
Group type: COMPARATOR
Intervention: Lying-down position
Number of subjects: 3236
Study 25938711 — intervention group
Group type: EXPERIMENTAL
Intervention: High-absorbency disposable diapers
Number of subjects: 0
Study 25938711 — intervention group
Group type: COMPARATOR
Intervention: Traditional low-absorbency cloth diapers
Number of subjects: 0
Study 23816967 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg per day
Number of subjects: 345
Study 23816967 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/pemetrexed
Number of subjects: 345
Study 22866006 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin (20 IU/kg)
Number of subjects: 12
Study 22866006 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination against Salmonella typhi
Number of subjects: 12
Study 22866006 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 12
Study 18752281 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate treatment
Number of subjects: 49
Study 18752281 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 49
Study 17531723 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA) with 0.2% ropivacaine
Number of subjects: 56
Study 17531723 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia (PCA) with meperidine
Number of subjects: 56
Study 15465984 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 162
Study 15465984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 10759649 — intervention group
Group type: EXPERIMENTAL
Intervention: N-butyl-2-cyanoacrylate (Tisuacryl)
Number of subjects: 130
Study 10759649 — intervention group
Group type: COMPARATOR
Intervention: Suture
Number of subjects: 130
Study 8825534 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (40 micrograms.kg‐1)
Number of subjects: 110
Study 8825534 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 110
Study 1488694 — intervention group
Group type: COMPARATOR
Intervention: ORS (30 cases)
Number of subjects: 62
Study 1488694 — intervention group
Group type: EXPERIMENTAL
Intervention: ORS and Smectite (3.6 g/day) (32 cases)
Number of subjects: 62
Study 1488694 — intervention group
Group type: EXPERIMENTAL
Intervention: ORS and Smectite (3.6 g/day)
Number of subjects: 62
Study 1488694 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study 3003729 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 to 40 mg/day)
Number of subjects: 32
Study 3003729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 3003729 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 32
Study 31904175 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hydrolyzed eggshell membrane (450 mg/d)
Number of subjects: 88